Russler-Germain et al. (2023)

Study Overview

In their 2023 study published in Blood Advances, Russler-Germain et al. conducted a comprehensive clinicogenomic analysis of 370 patients with follicular lymphoma (FL) or transformed FL (t-FL). The research aimed to elucidate the relationship between genetic alterations and patient outcomes, particularly focusing on mutations associated with disease progression. (Source)

Key Findings

Mutation Burden

  • No significant differences in mutation burden were observed among FL subsets categorized by grade, stage, watch-and-wait approach, or progression of disease within 24 months (POD24) status.
  • However, mutation burden was notably higher in relapsed/refractory FL and t-FL compared to newly diagnosed FL.

Specific Gene Mutations

  • CREBBP mutations were more prevalent in FL than in t-FL and were associated with shorter frontline progression-free survival (PFS) in FL patients.
  • Mutations in STAT6, TP53, IGLL5, B2M, SOCS1, and MYD88 were more common in relapsed/refractory FL or t-FL than in newly diagnosed FL.

Mutations Associated with Progression (MAP) Signature

  • The MAP signature was defined as the presence of two or more mutations among the seven genes: CREBBP, STAT6, TP53, IGLL5, B2M, SOCS1, and MYD88.
  • Patients with newly diagnosed FL possessing a MAP signature exhibited shorter frontline PFS, indicating a higher risk of disease progression.

Clinical Implications

  • The MAP signature may offer insights into FL progression risk, potentially providing a more generalizable prognostic tool than the m7-Follicular Lymphoma International Prognostic Index (m7-FLIPI).
  • Identifying patients with a MAP signature at diagnosis could facilitate the development of targeted therapeutic strategies and inform clinical decision-making.

Conclusion

Russler-Germain et al.’s study enhances the understanding of the genetic factors influencing FL progression. The identification of a MAP signature associated with inferior outcomes at diagnosis underscores the importance of genetic profiling in FL and highlights the potential for personalized treatment approaches in managing this heterogeneous disease.

Summary of novel genes

Entity Tier 1 genes Tier 2 genes Tier 3 genes
FL 2 18 0
--- config: sankey: showValues: true linkColor: target width: 600 height: 300 nodeAlignment: right prefix: '(' suffix: ' genes)' --- sankey-beta This study, New Tier 1, 2 New Tier 1, FL Tier 1, 2 This study, New Tier 2, 18 New Tier 2, FL Tier 2, 18 This study, New Tier 3, 0 New Tier 3, FL Tier 3, 0 All other FL studies, FL Tier 1, 52 All other FL studies, FL Tier 2, 41 All other FL studies, FL Tier 3, 0

Novel genes reported in this study

Tier 1

New gene FL tier
BCL10 1
CD83 1

Tier 2

New gene FL tier
ABL2 2
CD70 2
CILP 2
CYP2A6 2
GBP7 2
GRM6 2
IGLL5 2
KIR3DL1 2
MAGEC1 2
MAP7D1 2
MKI67 2
NFKBIA 2
OR8H2 2
PZP 2
SHROOM3 2
SRRM2 2
STAB2 2
XIRP2 2

Details

Russler-Germain, David A., Kilannin Krysiak, Cody A. Ramirez, Matthew Mosior, Marcus P. Watkins, Felicia Gomez, Zachary L. Skidmore, et al. 2023. “Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes at Diagnosis: Alliance A151303.” Blood Advances 7: 5524–39. https://doi.org/10.1182/bloodadvances.2023010779.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

In particular, let us know if you feel that an important citation is missing or if a paper has been cited incorrectly.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.